View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
June 25, 2019

Transplant reports positive results in kidney device trial

Transplant Biomedicals has reported positive interim results of the first-in-human clinical trial of the Vivian device in kidney transplantation.

Transplant Biomedicals has reported positive interim results of the first-in-human clinical trial of the Vivian device in kidney transplantation.

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

For the multi-centre, prospective, single-arm EMERGE trial, the company enrolled a total of 32 patients who received a kidney from either brain death standard and extended criteria donors (DBD ; SCD+ECD) or cardiac arrest donors (DCD MIII).

The trial has been designed to evaluate the safety and performance of the Vivian device for organ preservation in donor kidneys for transplantation.

Transplant Biomedicals completed patient enrolment for the trial in April this year.

The results highlighted an excellent safety profile and no events related with the device were reported.

The device was also associated with a low rate of delayed graft function (DGF ) at 30-days with a short duration of DGF .

Transplant Biomedicals co-founder and CSO Dr Carmen Peralta said: “These results are in full alignment with our pre-clinical experience and fully support the idea that our disrupting platform that combines hypothermia and low frequency/energy ultrasounds can play a relevant role in addressing the current unmet medical needs not covered by the standard-of-care in solid organ preservation, static cold storage.”

The proportion of recipients with DGF in the primary performance endpoint was 19%.

In the DBD and DCD subgroups, the rate of DGF was 25% and 16%, respectively.

Transplant Biomedicals CEO Dr Joan Salgado said: “These interim results in kidney transplantation represent a boost to our mission of improving the outcomes in solid organ transplantation and to continue and accelerate further our development activities in cell and tissue preservation.”

Related Companies

Free Report
img

Medical Device Industry Landscape In Asia-Pacific

GlobalData's APAC Medical Devices Industry Landscape – 2022 free study breaks down the APAC medical devices market by segment and region and includes insights on local and global competitors, pipeline product developments, clinical trials studies, and significant deals in the industry. The APAC medical device industry witnessed significant developments, launches, implementations, and adoption of new medical device technologies in the past decade, however the high cost of devices, regulatory hurdles, reimbursement pressure, and healthcare budget constraints have challenged market expansion across various territories and segments. APAC is the fastest growing regional market for medical device clinical trials, with China and Japan emerging as major clinical trial hotspots. The growth in medical device clinical trials in the APAC region is attributed to an increase in research partnerships between biopharma companies and clinical research organizations (CROs). This report also provides an in-depth analysis of the medical device market's opportunities and challenges, the influence of COVID-19 on the market, and government activities aimed to develop the APAC medical device market.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Medical Device Network